๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hormone Receptor-Positive Breast Cancer
Clinical trial register · China

Hormone Receptor-Positive Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 6 Beijing 4 Shanghai 2 Tianjin 2 Fuzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou6 Beijing4 Shanghai2 Tianjin2 Fuzhou1
All 12 locations
Target enrolment
to

Hormone Receptor-Positive Breast Cancer trials in China

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive๏ผŒ Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
NCT07796880Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
80
Guangzhou
2026-09-14
Recruiting
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
NCT07366112Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
Peking University People's Hospital
Phase 2
158
Beijing
2026-04-20
Not yet open
A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer
NCT07294339Acupuncture Treatment, Hormone Receptor-Positive Breast Cancer, Hot Flashes
Peking University People's Hospital
Not applicable
60
Beijing
2026-04-01
Recruiting
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
NCT07264998Breast Neoplasms, Hormone Receptor-Positive Breast Cancer, Abemaciclib, Abemaciclib-related Diarrhea
Hubei Cancer Hospital
Observational
60
Wuhan
2025-12-21
Recruiting
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
NCT06970912Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
Peking University People's Hospital
Phase 2
393
Beijing
2025-08-01
Recruiting
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
NCT07708194Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
94
Tianjin
2025-06-23
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
Active, closed
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
NCT06144944Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
160
Guangzhou
2024-01-17
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
NCT07073755Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer, HER2-positive Breast Cancer
Hunan Cancer Hospital
Observational
200
Changsha
2023-01-01
Active, closed
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
NCT05165225Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
48
Guangzhou
2021-07-13
Active, closed
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
NCT04872985Breast Cancer, Hormone-receptor Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
140
Guangzhou
2021-04-20
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/hormone-receptor-positive-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Hormone Receptor-Positive Breast Cancer.

How many Hormone Receptor-Positive Breast Cancer trials are recruiting in China?

8 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hormone Receptor-Positive Breast Cancer), 12 studies
PhaseStudiesRecruitingShare
Phase 25341.7%
Observational2216.7%
Phase 12216.7%
Not applicable108.3%
Phase 1/2118.3%
Phase 3108.3%

Most active sponsors

Lead sponsors with the most studies (Hormone Receptor-Positive Breast Cancer)
Lead sponsorStudiesRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University41
Peking University People's Hospital32
BeOne Medicines22
Hubei Cancer Hospital11
Hunan Cancer Hospital11
Tianjin Medical University Cancer Institute and Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.